期刊
ACS CHEMICAL NEUROSCIENCE
卷 8, 期 8, 页码 1688-1696出版社
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.7b00127
关键词
TRPV1; pain; vanilloid-binding site; capsaicin; tricyclic spirolactones; synthetic agonists
资金
- Israel Science Foundation [1368/12, 1444/16]
- State of Lower Saxony, Hannover, Germany
- Marie Curie Integration Grants [CIG 321746, 321899]
- German-Israeli Foundation (G.I.F.) [I-2330-1145.5/2012]
TRPV1 is a prominent signal integrator of the pain system, known to be activated by vanilloids, a family of endogenous and exogenous pain-evoking molecules, through the vanilloid-binding site (VBS). The extensive preclinical profiling of small molecule inhibitors provides intriguing evidence that TRPV1 inhibition can be a useful therapeutic approach. However, the dissimilarity of chemical species that activate TRPV1 creates a major obstacle to understanding the molecular mechanism of pain induction, which is viewed as a pivotal trait of the somatosensory system. Here, we establish the existence of a unique family of synthetic agonists that interface with TRPV1 through the VBS, containing none of the molecular domains previously believed to be required for this interaction. The overarching value obtained from our inquiry is the novel advancement of the existing TRPV1 activation model. These findings uncover new potential in the area of pain treatment, providing a novel synthetic platform.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据